ClinicalTrials.gg
RecruitingNCT07412782Updated Feb 17, 2026

REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)

An interventional study of REMS in Osteogenesis Imperfecta, Osteoporosis and Hypogonadisms, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 1 site in Italy. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Meyer Children's Hospital IRCCS · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
5 Years to 18 Years
Sex
All
01

Study summary

This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free ultrasound technology. Bone health is crucial during childhood, when peak bone mass develops, and reduced BMD is associated with increased fracture risk. DXA is the current reference method but has limitations in children, including radiation exposure and growth-related measurement issues. REMS has been validated in adults and shows promise in pediatrics, despite the lack of reference values. The study is a single-center, national, non-profit interventional study lasting about 12 months. Participants will undergo REMS BMD measurement, clinical history collection, and assessment of anthropometric and pubertal parameters, with prior DXA data collected when available. The primary aim is to describe BMD values measured by REMS in pediatric osteoporosis, with secondary aims including subgroup analyses and comparison with DXA. A sample of 100 patients is planned. Statistical analyses will assess BMD distributions, correlations with clinical variables, and agreement between REMS and DXA using correlation coefficients and Bland-Altman analysis.

02

Conditions studied

  • Osteogenesis Imperfecta
  • Osteoporosis
  • Hypogonadisms
  • Neoplasia
  • Obesity & Overweight
  • Malnutrition (Calorie)
  • Hypercortisolism
  • Growth Hormone Deficiency (GHD)
  • Osteopenia
03

In context

Osteogenesis Imperfecta

84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.

This study's planned enrollment of 100 is above the median of 28 across 60 interventional studies indexed under Osteogenesis Imperfecta.

Browse Osteogenesis Imperfecta studies →

Lead sponsor

Meyer Children's Hospital IRCCS is the lead sponsor of 78 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from adult patients or parents/legal guardians
  • Age between 5 and 18 years
  • Both sexes and all ethnicities
  • Known condition negatively affecting bone health

Exclusion criteria

Exclusion Criteria:

- Age below 5 years or over 18 years

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Diagnostic Test

    Diagnostic Test: REMS

Interventions

  • Diagnostic testREMS

    REMS (Radiofrequency Echographic Multi Spectrometry) technology, a non-invasive, radiation-free ultrasound system to detect BMD. REMS has obtained FDA and CE approval and has been validated

06

What researchers measure

Primary outcomes

  1. BMD values in primary osteoporosis

    Mean and median of Bone Mineral Density values obtained in the pediatric population affected by primary osteoporosis

    Time frame: At the enrollement

Secondary outcomes

  1. BMD values in pediatric patients with conditions negatively affecting bone health

    Mean and median of Bone Mineral Density values in pediatric patients with conditions negatively affecting bone health

    Time frame: At the enrollement

07

Study locations

1 of 1 sites recruiting
  • AOU IRCCS Meyer
    Florence, Tuscany 50100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07412782
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Stefano Stagi (MD, Meyer Children's Hospital IRCCS) — Principal investigator
First posted
Feb 17, 2026
Start date
Dec 4, 2025
Primary completion
Jun 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Stefano Stagi, Professor
Contact
stefano.stagi@unifi.it
0039 0555662305

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion